SPOTLIGHT: Geron gains milestone from Merck

Merck has filed an IND for a cancer vaccine candidate that targets telomerase, triggering a $4 million milestone payment to licensing partner Geron. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.